Stay updated with breaking news from Pharm Gmb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Original-Research: HAEMATO AG - von GBC AGEinstufung von GBC AG zu HAEMATO AGUnternehmen: HAEMATO AGISIN: DE000A289VV1Anlass der Studie: Research CommentEmpfehlung: BuyKursziel: 50.10 EURKursziel auf Sicht von: 31.12.2022Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel GoldmannPCR PoC-Device added to the produc...
Investegate announcements from HAEMATO AG, Original-Research: HAEMATO AG (von GBC AG): Buy
/PRNewswire/ -- The "CBD Consumer Health Market Research Report by Product, by Distribution Channel, by Region - Global Forecast to 2027 - Cumulative Impact of...
/PRNewswire/ -- The "CBD Consumer Health Market Research Report by Product, by Distribution Channel, by Region - Global Forecast to 2027 - Cumulative Impact of...
/PRNewswire/ -- FinancialNewsMedia.com News Commentary - The rise in consumer knowledge toward CBD infused FMCG product and ready product availability is...